New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
08:08 EDTAEGRAegerion initiates Phase 3 clinical trial for lomitapide in Japan
Aegerion Pharmaceuticals announced that patient enrollment has been initiated in Japan in a clinical trial of lomitapide as an adjunct treatment to reduce low-density lipoprotein cholesterol, or LDL-C, in Japanese patients with homozygous familial hypercholesterolemia, or HoFH. Last year, Aegerion received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for lomitapide. The phase three, open-label trial in Japan is similar in design to the completed Phase 3 trial conducted in the United States and other countries. Estimated enrollment is between five and 10 adult HoFH patients who are receiving concomitant lipid-lowering therapies, including, in some cases, apheresis. After a six week run-in period, patients will receive lomitapide for 26 weeks, starting at 5 mg/day and escalating to a maximum dose of 60 mg based on tolerability. After 26 weeks, patients will enter a 30 week safety phase. The primary endpoint is % change in LDL-C levels from baseline to week 26. Secondary endpoints include % change in lipid parameters, long-term safety, and changes in hepatic fat from baseline to week 56. The Japanese regulatory authorities have indicated they will allow the new drug application to be filed following completion of the 26 week efficacy phase.
News For AEGR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
09:28 EDTAEGRAegerion board backs CEO amid drug claims, TheStreet reports
Subscribe for More Information
October 27, 2014
10:52 EDTAEGRSeattle Genetics, Aegerion CEOs accused of drug use in lawsuit, TheStreet says
Subscribe for More Information
October 22, 2014
07:35 EDTAEGRCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 20, 2014
07:24 EDTAEGRAegerion price target lowered to $46 from $66 at Leerink
Leerink lowered its price target for Aegerion shares to $46 after its survey of 40 U.S. cardiologists implied a more bearish outlook for Juxtapid once PCSK9s emerge. The firm, however, believes new patient adds are well outpacing Juxtapid discontinuations in the near term. It keeps an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use